Funding Clinical Trials
Funding Clinical Trials
Our Agency funds clinical trials testing promising stem cell or gene therapies for currently incurable diseases or disorders to help patients with unmet medical needs. For basic information about stem cell trials, visit our Clinical Trials 101 page. For a list of clinical trials that are a result of early-stage CIRM grants click here.
CIRM Clinical Dashboard
| Disease Areas | Investigator | Organization | Phase |
Trial Status |
Targeted Enrollment | Detail |
|---|---|---|---|---|---|---|
|
Thomas Kipps | University of California, San Diego | Phase 1/2 | Active, not recruiting | 102 | |
|
Mark Chao | Forty Seven Inc. | Phase 1 | Active, not recruiting | 258 | |
|
Michael Pulsipher | Children's Hospital of Los Angeles | Phase 1/2 | Active, not recruiting | 60 | |
|
Colleen Delaney | Nohla Therapeutics Inc | Phase 2 | Closed | 146 | |
|
Rajesh Belani | Poseida Therapeutics, Inc. | Phase 1 | Closed | 105 | |
| Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1 | Completed | 10 | ||
| Thomas Kipps | University of California, San Diego | Phase 1 | Completed | 26 | ||
| Irving Weissman | Stanford University | Phase 1 | Completed | 88 | ||
| Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1 | Completed | 42 | ||
|
Mehrdad Abedi | University of California, Davis | Phase 1/2 | Recruiting | 18 | |
|
David Miklos | Stanford University | Phase 1 | Recruiting | 60 | |
|
Joseph Woodard | Immune-Onc Therapeutics | Phase 1 | Recruiting | 122 | |
|
Matthew Porteus | Stanford University | Phase 1 | Recruiting | 22 | |
|
Paul Finnegan | Angiocrine Bioscience, Inc. | Phase 3 | Recruiting | 148 |
